Summary of COVID-19 varespladib studies

1. Lickteig et al., A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2

18 patient varespladib late treatment RCT: 120% higher mortality (p=1), 240% higher ventilation (p=1), and 240% higher progression (p=1).
Very small early terminated RCT showing no significant differences with varespladib treatment.
Nov 2022, NCT04969991, https://clinicaltrials.gov/study/NCT04969991, https://c19p.org/lickteig